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Abstract. In time-to-event settings, the presence of competing events compli-
cates the definition of causal effects. Here we propose the new separable effects
to study the causal effect of a treatment on an event of interest. The separable
direct effect is the treatment effect on the event of interest not mediated by its
effect on the competing event. The separable indirect effect is the treatment effect
on the event of interest only through its effect on the competing event. Similar to
Robins and Richardson’s extended graphical approach for mediation analysis, the
separable effects can only be identified under the assumption that the treatment
can be decomposed into two distinct components that exert their effects through
distinct causal pathways. Unlike existing definitions of causal effects in the pres-
ence of competing events, our estimands do not require cross-world contrasts or
hypothetical interventions to prevent death. As an illustration, we apply our
approach to a randomized clinical trial on estrogen therapy in individuals with
prostate cancer.
1. Introduction
A competing event is any event that makes it impossible for the event of inter-
est to occur. For example, consider a randomized trial to estimate the effect of a
new treatment on the 3-year risk of prostate cancer in which 1000 individuals with
prostate cancer were assigned to the treatment and 1000 to placebo. All partici-
pants adhered to the protocol and remained under follow-up. After 3 years, 100
individuals in the treatment arm and 200 in the placebo arm died of prostate can-
cer. Also, 150 individuals in the treatment arm and 50 in the placebo arm died of
other causes (e.g., cardiovascular disease). Death from cardiovascular disease is a
competing event for death from prostate cancer: individuals who die of cardiovas-
cular disease cannot subsequently die of prostate cancer. When competing events
are present, several causal estimands may be considered to define the causal effect
of treatment on a time-to-event outcome [1].
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2Consider first the total treatment effect [1] defined by the contrast of the cu-
mulative incidence (risk) [2, 3] of the event of interest under different treatment
values. In our example, the total treatment effect on death from prostate cancer is
the contrast of the cumulative incidence of death from prostate cancer under treat-
ment, consistently estimated by 100
1000
, and under placebo, consistently estimated by
200
1000
. Therefore, the estimate of the total treatment effect on the additive scale is
100
1000
− 200
1000
= −0.1, which indicates that treatment reduced the risk of death from
prostate cancer.
However, in our trial, the interpretation of the total treatment effect on the
event of interest is difficult because the treatment also increased the risk of the
competing event. The estimate of the total effect of treatment on the competing
event is 150
1000
− 50
1000
= 0.1 on the additive scale. Thus, it is possible that the beneficial
effect of treatment on death from prostate cancer is simply a consequence of the
harmful effect of treatment on death from other causes: when more people die from
other causes, fewer people can die from prostate cancer. Note that this problem of
interpretation cannot be solved by considering contrasts of hazard functions, such
as cause-specific and subdistribution hazards, because these estimands are defined
conditional on a post-treatment event (survival) and therefore do not generally have
a causal interpretation [1, 4].
One way to deal with this problem is to consider a second causal estimand on
the risk scale: the (controlled) direct effect of treatment on the event of interest not
mediated by the effect of treatment on the competing events, that is, the effect of
treatment if we had somehow intervened to eliminate all competing events. This
estimand corresponds to defining the competing events as censoring events [1], and
is sometimes denoted the marginal (net) distribution function. Unlike the total
effect, identification of the controlled direct effect requires untestable assumptions
even in an ideal randomized trial with perfect adherence and no loss to follow-up [1].
Also, this causal estimand often introduces a new conceptual challenge: the direct
effect is not sufficiently well-defined because there is no scientific agreement as to
which hypothetical intervention, if any, would eliminate the competing events [5].
For example, in our prostate cancer trial, no intervention has ever been proposed
that can prevent all deaths from causes other than prostate cancer. As a byproduct
of the ill-defined intervention to prevent competing events, effect estimates cannot
be empirically verified – not even in principle – in a randomized experiment.
A third causal estimand is the survivor average causal effect (SACE) [6], which
is the total treatment effect (on the risk scale) in the principal stratum of patients
who would never experience the competing event under either level of treatment
[1, 7, 8]. Unlike the total effect, the presence of competing events is not a problem
when interpreting the SACE, because the SACE is restricted to subjects who do not
experience competing events. However, identification of the SACE requires strong
untestable assumptions, e.g. about cross-world counterfactuals, even in a perfectly
executed trial. Also, the SACE could never, even in principle, be confirmed in
a real-world experiment as it will never be possible to observe the status of the
competing event for the same individual under two different levels of treatment.
The problems of the previous estimands can be overcome in settings in which the
treatment exerts its effect on the event of interest and its effect on the competing
event through different causal pathways. Here, we define the separable direct and
indirect effects for settings with competing events. Like the controlled direct effect
3and the SACE, identification of separable effects relies on untestable assumptions
even when the treatment is randomized. However, unlike the controlled direct
effect and the SACE, separable effects do not require conceptual interventions on
competing events or knowledge of cross-world counterfactuals; the separable effects
are well-defined if we can articulate a hypothetical decomposition of the treatment
into two components. Therefore, in principle, they may be verified in a future
experiment. Our definitions of separable effects and conditions for identifiability
follow from the work of Robins and Richardson [9] and Didelez [10], who provided
estimands for direct and indirect effects in mediation analysis which do not require
cross-world assumptions.
We have organized the paper as follows. In Section 2, we describe the observed
data structure. In Section 3, we present a conceptual treatment decomposition and
provide explicit examples to fix ideas. In Section 4, we formulate the causal estimand
and define the new separable effects. In Section 5, we present conditions that allow
for identifiability of the separable effects. In Section 6, we give 3 different estimators
for the separable effects that can be implemented with standard statistical models,
and we use data from a randomized clinical trial to estimate a direct effect of
estrogen therapy on prostate cancer mortality. In Section 7, we provide a final
discussion of the new estimands.
2. Observed data structure
We consider a study in which individuals are randomly assigned to a binary
treatment A ∈ {0, 1} at baseline (e.g. A = 1 if assigned to treatment and A = 0
if assigned to placebo). Let L ∈ L denote a vector of individual pretreatment
characteristics. For each of equally spaced discrete time intervals k = 0, 1, 2..., K+1,
let Yk and Dk denote indicators of an event of interest and a competing event by
interval k, respectively. In our example, Yk denotes death due to prostate cancer
and Dk death from other causes by interval k. We adopt the convention that Dk is
measured just before Yk. If an individual experiences the competing event at time k
without a history of the event of interest (Dk = 1, Yk−1 = 0), then all future values
of the event of interest are zero. We can approximate a continuous time setting by
choosing time intervals that are arbitrary small.
By definition, D0 ≡ Y0 ≡ 0, that is, no individual experiences any event during
the initial interval. We use overbars to denote the history of a random variable,
such that Y¯k = (Y1, Y2, ..., Yk) is the history of the event of interest through interval
k. Similarly, we use underbars to denote future values of a random variable, such
that Yk = (Yk, Yk+1, ..., YK+1). We assume full adherence to the assigned treatment
without loss of generality, and until Section 5.4, no loss to follow-up.
3. Decomposition of treatment effects
Suppose that treatment A can be conceptualized as having two binary compo-
nents that act through different causal pathways: one component AY that affects
the event of interest Yk and one component AD that affects the competing event
Dk. In the observed data, AY and AD are deterministically related,
A ≡ AD ≡ AY .(1)
Although (1) holds in the observed data, we must conceive hypothetical interven-
tions that set AD and AY to different values when we define the separable effects,
4and we require that setting A = a is equivalent to setting both AY and AD to a,
that is,
Y aY =aD=ak+1 = Y
a
k+1.(2)
The causal diagram in Figure 1 represents this decomposition in a setting with a
single time point. The bold arrows represent the deterministic relation (1). The de-
composition of treatment into two distinct components must be justified by subject-
matter knowledge. Let us consider two examples.
3.1. Diethylstilbestrol and prostate cancer mortality. In our prostate cancer
example, we assume that A can be decomposed into a component AY that directly
affects death from prostate cancer and a component AD that directly affects death
from other causes. Suppose that treatment A = 0 is placebo and A = 1 is diethyl-
stilbestrol (DES), an estrogen which is thought to reduce mortality due to prostate
cancer by suppressing testosterone production and to increase cardiovascular mor-
tality through estrogen-induced synthesis of coagulation factors [11].
We could then consider a hypothetical treatment that has the same direct ef-
fect as DES on prostate cancer mortality, but lacks any effect effect on mortality
from other causes; that is, the same effect as the AY component of DES when
the AD component is removed. Real-life treatments similar to such a hypothetical
treatment are luteinizing hormone releasing hormone (LHRH) antagonists or or-
chidectomy (castration), which reduce testosterone production, but lack estrogen
induced effects.
Also, we could consider a hypothetical treatment that has the same direct effect
as DES on mortality from other causes, but that lacks any effect on prostate can-
cer mortality; that is, the same effect as the AD component of DES when the AY
component is removed. In practice, a drug that contains not only DES but also
testosterone may resemble this hypothetical treatment, as the additional testos-
terone component will nullify the testosterone suppression that is induced by DES.
3.2. Statins and dementia. Consider a study to quantify the effect of statins
on dementia. Statins reduce cardiovascular mortality by lowering the cholesterol
production in the liver. As dementia may develop due to microvascular events in the
small cerebral arteries, lowering cholesterol may also reduce the risk of dementia.
When studying the effect of statins on dementia, death will be a competing event.
Because statins appear to reduce mortality and dementia through the same mech-
anism, i.e., lowering the cholesterol levels in the blood, decomposing A into the
distinct components AY and AD would be difficult. One possibility might be to
leverage the distinct localization of the microvessels in the brain: we could bioengi-
neer a cholesterol transporter, which is surgically implanted to shuttle cholesterol
particles from the distal cerebral arteries directly to the large cerebral veins, cir-
cumventing the cerebral microvessels. That is, if Yk and Dk denote dementia and
death, respectively, then carriers of the transporter will have the AY component of
statins on dementia, but they will lack the AD component of statins on mortality.
Robins and Richardson discussed the construction of plausible interventions in a
mediation context, using nicotine in cigarettes as an example [9, Section 5.2].
3.3. Practical considerations. Whenever the decomposition of treatment A into
AY and AD is possible in principle, regardless of whether it is possible in practice at
this time in history, the effects of AY and AD are well-defined. Therefore, in both
5examples above, we described well-defined effects even though the decomposition
of treatment may be practically possible in the prostate cancer example but not in
the statin example.
However, caution is required when considering treatment decompositions that, as
in the statins example, are possible in principle but not in practice. The problem
is that practically impossible decompositions make it hard to evaluate the identifi-
ability conditions for the effects of each component. As described in Section 5, the
identification of the separable effects is based on the unverifiable condition that AY
and AD are treatment components actually operating in the data [5], such that AY
has no direct effect on Dk and that AD has no direct effect on Yk. When relying
on convoluted treatment decompositions, as in our statins example, we may be less
confident that these conditions hold in the data. Of course, if these conditions are
violated, our effect estimates may differ from those that would be obtained in an
experiment in which individuals are randomized to our AY and AD.
On the other hand, a careful definition of treatment decomposition may help
ground scientific conversations even if the decomposition is not yet possible. For
example, it is debated whether statins have a protective effect on dementia [12]. To
clarify the notion of a ’protective effect’ it would be helpful to consider a hypothet-
ical trial in which subjects were randomly assigned to the cholesterol transporter
or placebo.
4. Definition of separable effects
For k ∈ (0, 1, ..., K), let Y ak+1 be an individual’s event of interest at time k + 1
when, possibly contrary to fact, A is set to the value a ∈ {0, 1}. Then the causal
effect of treatment A at time k+ 1 is Pr(Y a=1k+1 = 1)−Pr(Y a=0k+1 = 1) on the additive
scale.
Let Y aY ,aDk+1 be an individual’s value of Yk+1 when, possibly contrary to fact, AY
is set to aY and AD is set to aD, where aY , aD ∈ {0, 1}. We can now define the
separable direct effects of treatment on the event of interest as the contrasts
Pr(Y aY =1,aDk+1 = 1) vs. Pr(Y
aY =0,aD
k+1 = 1)
for aD = 1 or aD = 0; that is, the effect of the component of treatment that
affects the event of interest AY when the component of treatment that affects the
competing event AD is set at a constant value aD.
Analogously, we can define the separable indirect effects of treatment on the event
of interest as the contrasts
Pr(Y aY ,aD=1k+1 = 1) vs. Pr(Y
aY ,aD=0
k+1 = 1),
for aY = 1 and aY = 0; that is, the effect of the component of treatment that affects
the competing event AD when the component of treatment that affects the event
of interest AY is set at a constant value aY . In other words, the separable indirect
effects are functions of the treatment component AD that affects the competing
event Dk+1, and the separable indirect effects arise because the competing event
makes it impossible for the event of interest to occur.
6From (2) we find that the sum of separable direct and indirect effects (on the
additive scale) equals the total effect,
[Pr(Y aY =1,aD=1k+1 = 1)− Pr(Y aY =0,aD=1k+1 = 1)]
+ [Pr(Y aY =0,aD=1k+1 = 1)− Pr(Y aY =0,aD=0k+1 = 1)]
= Pr(Y a=1k+1 = 1)− Pr(Y a=0k+1 = 1).
To provide intuition about the magnitude of the separable effects, we describe 4
illustrative scenarios in Appendix A.
5. Identification of separable effects
The identification of the separable effects requires the identification of the quan-
tities
Pr(Y aY ,aDk+1 = 1),(3)
where aY , aD ∈ {0, 1}. Identifying these quantities would be straightforward if each
of the treatment components could be separately intervened upon, that is, if we
could conduct a randomized experiment with 4 possible treatment arms defined by
the 4 combinations of values of AY and AD. However, when using data from a
study like that of Section 2, in which only the treatment A is randomized, we only
observe 2 out of the 4 treatment arms in a hypothetical trial in which AY and AD
were randomized. As a result, we need additional untestable conditions to identify
(3).
5.1. Identifiability conditions. First, we need exchangeability conditional on the
measured covariates L,
Y¯ aK+1, D¯
a
K+1 ⊥ A | L for all a,
where time K+1 is the end of the study. This exchangeability condition is expected
to hold when A ≡ AY ≡ AD is randomized.
Second, consistency, such that if A = a, then
Y ak+1 = Yk+1
Dak+1 = Dk+1,
for a = 0, 1 at all times k = 0, 1, ..., K. If any subject has data history consistent
with the intervention under a counterfactual scenario, then the consistency assump-
tion ensures that the observed outcome is equal to the counterfactual outcome.
Third, positivity such that
Pr(L) > 0 =⇒
Pr(A = a | L) > 0 w.p.1,(4)
which is the usual positivity condition under interventions on A. However, our esti-
mand is based on hypothetical intervention on both AY and AD, and our positivity
condition does not ensure the stricter condition
f(L) > 0 =⇒
Pr(AY = aY , AD = aD | L) > 0 w.p.1,
which, indeed, will be violated when aY 6= aD in our setting where A ≡ AY ≡ AD.
7To allow for identifiability under our positivity condition in (4), we introduce two
conditions that are related to conditions described by Didelez in a mediation setting
[10].
Dismissible component condition 1.
∆1 : Pr(Y aY ,aD=1k+1 = 1 | Y aY ,aD=1k = 0, DaY ,aD=1k+1 = 0, L = l)
= Pr(Y aY ,aD=0k+1 = 1 | Y aY ,aD=0k = 0, DaY ,aD=0k+1 = 0, L = l),
at all times k = 0, 1, ..., K. That is, the counterfactual (discrete-time) hazards of
the event of interest are equal under all values of AD.
Dismissible component condition 2.
∆2 : Pr(DaY =1,aDk+1 = 1 | Y aY =1,aDk = 0, DaY =1,aDk = 0, L = l)
= Pr(DaY =0,aDk+1 = 1 | Y aY =0,aDk = 0, DaY =0,aDk = 0, L = l),
at all times k = 0, 1, ..., K. That is, the counterfactual (discrete-time) hazard
functions of the competing event are equal under all values of AY .
By considering a hypothetical trial in which both AY and AD are randomized,
we can define conditional independencies that imply the dismissible component
conditions, and these conditional independencies can be read off of causal DAGs
directly, see Appendix B for details.
The dismissible component conditions ensure that we can adjust for common
causes of Dk and Yk′ for all k, k
′ ∈ (1, 2, ..., K + 1). In particular, an unmeasured
common cause of Yk and Dk, such as UY D in Figure 2, violates ∆1 and ∆2. In
our prostate cancer example, suppose that smoking is a common cause of death
from prostate cancer (YK) and death from other causes (Dk). Then, if smoking
is an unmeasured variable (such as UY D in Figure 2), the dismissible component
conditions will be violated.
However, the presence of unmeasured causes UY of Yk and unmeasured causes UD
ofDk, as shown in Figure 3, does not violate ∆1 and ∆2 (see Appendix E for details);
it just implies that the hazard terms in (5) cannot be causally interpreted due to
conditioning on a collider [1, 4, 13], which is analogous to the mediation setting in
Didelez [10, Figure 6]. For this reason, we have defined our causal estimands as
contrasts of risks rather than as contrasts of hazards. Furthermore, adjusting for a
common cause of Yk and Dk, such as L in Figure 4, allows identification under ∆1
and ∆2. In subsequent figures we have omitted the variables UY and UD to avoid
clutter, but our results are valid in the presence of UY and UD. We have also omitted
an arrow from L to A, but this arrow would not invalidate our results. Furthermore,
we have intentionally omitted arrows from Dk to Ys for k < s, as these arrows are
redundant in our setting where the competing event is a terminating event that
precludes the event of interest at all subsequent times. The dismissible component
conditions are not empirically verifiable in a trial in which the entire treatment
A, but neither of its components AY and AD, is intervened upon. However, both
conditions could be tested in a trial in which AY and AD were randomly assigned.
5.2. Identification formula. Under the identifiability conditions in Section 5.1,
we identify Pr(Y aY ,aDk+1 = 1) from the following g-functional [7] of the observed data
8described in Section 2,∑
l
[ k∑
s=0
Pr(Ys+1 = 1 | Ds+1 = Ys = 0, A = aY , L = l)
s∏
j=0
[
Pr(Dj+1 = 0 | Dj = Yj = 0, A = aD, L = l)
× Pr(Yj = 0 | Dj = Yj−1 = 0, A = aY , L = l)
]]
Pr(L = l),
(5)
see Appendix C for proof.
5.3. Intuition on the identification formula (5) and falsifiability of the
separable effects. Identification formula (5) can be intuitively motivated as fol-
lows: consider an experiment G in which both AY and AD are randomly assigned
independently of each other such that AY ⊥ AD in G. In the experiment G,
Pr(Y aY ,aDk+1 = 0) = Pr(Yk+1 = 0 | AY = aY , AD = aD) by randomization. By the
laws of probability Pr(Yk+1 = 0 | AY = aY , AD = aD) can in turn be re-expressed
as: ∑
l
[ k∑
s=0
Pr(Ys+1 = 1 | Ds+1 = Ys = 0, AY = aY , AD = aD, L = l)
s∏
j=0
[
Pr(Dj+1 = 0 | Dj = Yj = 0, AY = aY , AD = aD, L = l)
× Pr(Yj = 0 | Dj = Yj−1 = 0, AY = aY , AD = aD, L = l)
]]
Pr(L = l).
(6)
Formula (5) can be obtained by applying the dismissible component conditions to
the terms in (6). These additional conditions are needed for identification in our
current study because, unlike in G, only A was randomized in our current study
and not the separate components AY and AD. If the experiment G is actually
conducted in the future, then the separable effect estimates obtained from (5) in
our current study can be confirmed by comparing them to estimates of Pr(Yk+1 =
0 | AY = aY , AD = aD) from G [9].
Note that (5) can also be read off of a Single World Intervention Graph (SWIG)
[14] that satisfies the dismissible component conditions, as suggested in Figure 5,
illustrating that the separable effects are single-world quantities that are empirically
testable in principle. This is in contrast to alternative approaches from mediation
analysis that require additional, untestable cross-world independence assumptions
[9].
5.4. Separable effects in the presence of censoring. We consider a subject to
be censored at time k+1 if the subject remained under follow-up and was event-free
until k, but we have no information about the subject’s events at k+ 1 or later [1].
That is, censoring is a type of event that does not make it impossible for the event
of interest to occur and we assume that censoring can in principle be prevented
9[1]. When the censoring is independent of future counterfactual events given L, as
illustrated in Figure 6, we can identify the separable effects from∑
l
[ K∑
s=0
Pr(Ys+1 = 1 | Ds+1 = Ys = C¯s+1 = 0, A = aY , L = l)
s∏
j=0
[
Pr(Dj+1 = 0 | Dj = Yj = C¯j+1 = 0, A = aD, L = l)
× Pr(Yj = 0 | Dj = Yj−1 = C¯j = 0, A = aY , L = l)
]]
Pr(L = l),
(7)
where Ck is an indicator of being censored at k, see Appendix C for details. Alterna-
tively, the identification formula can be derived by drawing a SWIG for the scenario
of interest, as suggested in Figure 7. Hereafter we will use νaY ,aD,k to denote the
g-formula (5).
5.5. Alternative representations of the identification formula. The g-formula
(7) can also be expressed as
k∑
s=0
E[WC,s(aY )WD,s(aY , aD)(1− Ys)(1−Ds+1)Ys+1 | A = aY ],(8)
where
WD,s(aY , aD) =
∏s
j=0 Pr(Dj+1 = 0 | C¯j+1 = Dj = Yj = 0, L, A = aD)∏s
j=0 Pr(Dj+1 = 0 | C¯j+1 = Dj = Yj = 0, L, A = aY )
,
WC,s(aD) =
I(C¯s+1 = 0)∏s
j=0 Pr(C¯j+1 = 0 | C¯j = Dj = Yj = 0, L, A = aD)
,
see Appendix D for details. Furthermore, another representation of (7) is
k∑
s=0
E{WC,s(aD)WY,s(aD, aY )(1− Ys)(1−Ds+1)Ys+1 | A = aD},(9)
where WC,s(aD) is defined as in (8) and
WY,s(aD, aY ) =
Pr(Ys+1 = 1 | C¯s+1 = Ds+1 = Ys = 0, L, A = aY )
Pr(Ys+1 = 1 | C¯s+1 = Ds+1 = Ys = 0, L, A = aD)
×
∏s−1
j=0 Pr(Yj+1 = 0 | C¯j+1 = Dj+1 = Yj = 0, L, A = aY )∏s−1
j=0 Pr(Yj+1 = 0 | C¯j+1 = Dj+1 = Yj = 0, L, A = aD)
,
as formally shown in Appendix D. Note that in settings without censoring, WC,s(a) ≡
1, a = 0, 1. Representations (8) and (9) motivate inverse probability (IP) weighted
estimators of the separable effects, as described in Section 6.
6. Estimation of separable effects
To estimate the separable effects, we emphasize that (5) and (7) are functionals of
(discrete-time) hazard functions and the density of L. Indeed, Pr(Yk+1 = 1 | Dk+1 =
Yk = C¯k+1 = 0, A = a, L = l) and Pr(Dk+1 = 0 | Dk = Yk = C¯k+1 = 0, A = a, L =
l) are often denoted ’cause specific hazard functions’ in the statistical literature.
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Though the term ’cause specific’ is confusing because the causal interpretation of
these hazard functions is ambiguous [1], we can nevertheless estimate these functions
using classical statistical models, such as multiplicative or additive hazard models.
Provided that these hazard models are correctly specified, along with Pr(L) [15], we
can consistently estimate (7) using a parametric g-formula estimator [7]. However,
we can also derive weighted estimators that rely on fewer model assumptions.
6.1. IP weighted estimators. Motivated by the alternative g-formula represen-
tation (8), define
WˆD,k,i(aY , aD; ηˆD) =
∏k
j=0 Pr(Dj+1 = 0 | C¯j+1 = Dj = Yj = 0, Li, A = aD; ηˆD)∏k
j=0 Pr(Dj+1 = 0 | C¯j+1 = Dj = Yj = 0, Li, A = aY ; ηˆD)
,
WˆC,k,i(aD; ηˆC) =
I(C¯k+1 = 0)∏k
j=0 Pr(C¯j+1 = 0 | C¯j = Dj = Yj = 0, Li, A = aD; ηˆC)
,
where Pr(Dj+1 = 0 | C¯j+1 = Dj = Yj = 0, L, A = aD; ηD) is a parametric model for
the numerator (and denominator) of WD,k(aY , aD) indexed by parameter ηD, and
ηˆD is a consistent estimator of ηD (e.g. the MLE), and the terms in WˆC,k,i(aD; ηˆC)
are defined similarly, where ηˆC is a consistent estimator of ηC .
Let η1 = (ηD, ηC), and define the estimator νˆ1,aY ,aD,k of νaY ,aD,k as the solution to
the estimating equation
∑n
i=1 U1,k,i(νaY ,aD,k, ηˆ1) = 0 with respect to νaY ,aD,k with
U1,k,i(νaY ,aD,k, ηˆ1)
=I(Ai = aY )
[ k∑
s=0
{Wˆ1,s,i(aY , aD; ηˆ1)Ys+1,i(1− Ys,i)(1−Ds+1,i)} − νaY ,aD,k
]
,
and Wˆ1,s,i(aY , aD; ηˆ1) = WˆD,s,i(aY , aD; ηˆD)WˆC,s,i(aY ; ηˆC).
Then, νˆ1,aY ,aD,k is a consistent estimator for νaY ,aD,k if the models indexed by
elements in η1 are correctly specified and ηˆ1 is a consistent estimator for η1, which
follows because (7) and (8) are equal. For example, we can use conventional sta-
tistical models for binary outcomes, such as pooled logistic regression models, to
estimate the weights WD,k(aY , aD) and WC,k(aY ).
Analogous to νˆ1,aY ,aD,k, we can derive an estimator based on (9). Suppose
WˆY,k,i(aD, aY ; ηˆY ) =
Pr(Yk+1 = 1 | C¯k+1 = Dk+1 = Yk = 0, Li, A = aY ; ηˆY )
Pr(Yk+1 = 1 | C¯j+1 = Dk+1 = Yk = 0, Li, A = aD; ηˆY )
×
∏k−1
j=0 Pr(Yj+1 = 0 | C¯j+1 = Dj+1 = Yj = 0, Li, A = aY ; ηˆY )∏k−1
j=0 Pr(Yj+1 = 0 | C¯j+1 = Dj+1 = Yj = 0, Li, A = aD; ηˆY )
,
where the terms in WˆY,k,i(aD, aY ; ηˆY ) are statistical models for binary outcomes and
ηˆY is a consistent estimator for ηY .
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Let η2 = (ηY , ηC), and define the estimator νˆ2,aY ,aD,k of νaY ,aD,k as the solution to
the estimating equation
∑n
i=1 U2,k,i(νaY ,aD,k, ηˆ2) = 0 with respect to νaY ,aD,k, where
U2,k,i(νaY ,aD,k, ηˆ2)
=I(Ai = aD)
[ k∑
s=0
{Wˆ2,s,i(aY , aD; ηˆ2)Ys+1,i(1− Ys,i)(1−Ds+1,i)} − νaY ,aD,k
]
,
and Wˆ2,s,i(aY , aD; ηˆ2) = WˆC,s,i(aD; ηˆC)WˆY,s,i(aD, aY ; ηˆY ). Analogous to the estima-
tor based on (8), provided that the models indexed by elements in η2 are correctly
specified and ηˆ2 is a consistent estimator for η2, then consistency of νˆ2,aY ,aD,k for
νaY ,aD,k follows because (7) and (9) are equal.
In the next section, we use this approach to analyze a randomized trial on prostate
cancer therapy. In Appendix F, we also present simulations, suggesting that the
estimators perform satisfactory in finite samples. The simulations also illustrate
that the separable effect can be substantially different than the total effect, and that
the estimators may be biased if the dismissible component conditions are violated.
6.2. Example: A randomized trial of prostate cancer. Consider, as described
in Section 3.1, a hypothetical drug that has the same direct effect as DES on
prostate cancer mortality (same AY component), but lacks any effect on mortal-
ity due to other causes (opposite AD component). Then we can define separable
direct effects of treatment DES on prostate cancer mortality Yk in the presence
of competing mortality Dk from other causes. We estimated these separable ef-
fects using a parametric g-formula estimator and, for simplicity, one of the IP
weighted estimators (νˆ1,aY ,aD,k). We used publicly available data from a random-
ized trial (http://biostat.mc.vanderbilt.edu/DataSets) [16] that has been used in
several methodological articles on competing risks [17, 18, 19, 20]. In total, 502
patients were assigned to 4 different treatment arms. We restrict our analysis to
the placebo arm (127 patients) and the high-dose DES arm (125 patients).
To implement the parametric g-formula estimator, we used pooled logistic regres-
sion models to estimate the terms in (7), in which daily activity function, age group,
hemoglobin level and previous cardiovascular disease were included as covariates (L
in Figure 6), that is,
logit[Pr(Yk = 1 | Dk = Yk−1 = C¯k = 0, A, L)] = θ0,k + θ1A+ θ2Ak + θ3Ak2 + θ′4L
(10)
logit[Pr(Dk = 1 | Dk−1 = Yk−1 = C¯k = 0, A, L)] = β0,k + β1A+ β2Ak + β3Ak2 + β′4L,
(11)
where θ0,k and β0,k are time-varying intercepts modeled as cubic polynomials. To
allow time-varying treatment effects, we included θ2, θ3, β2 and β3.
To implement the IP weighted estimator νˆ1,aY ,aD,k, we only require the model
(11) (similarly, we would only require the model (10) to implement νˆ2,aY ,aD,k).
Both the parametric g-formula and IP weighted estimator gave cumulative inci-
dence estimates under the hypothetical drug that were similar, but not identical,
to those under DES treatment. Table 1 displays estimates of the 3-year cumulative
incidence and 95% bootstrap confidence intervals based on both estimators and
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Figure 8B shows cumulative incidence curves from the IP weighted estimator (R
code is provided found in the supplementary material).
Table 1. Estimates of cumulative incidence after 3 years of follow-up.
Estimand G-formula estimate (95%CI) IP weighted estimate (95%CI)
Pr(Y a=136 = 1) 0.14 (0.08-0.20) 0.17 (0.10, 0.24)
Pr(Y aY =1,aD=036 = 1) 0.15 (0.09-0.21) 0.18 (0.10, 0.26)
Pr(Y a=036 = 1) 0.21 (0.15-0.28) 0.23 (0.17, 0.35)
Our analysis suggests that DES mostly reduces prostate cancer mortality via
testosterone suppression because the estimate of the separable indirect effect on
3-year mortality is close to zero. Using either the parametric g-formula or the IP
weighted estimator, the estimate of the additive indirect effect after 3 years of follow-
up is 0.01 (0.15− 0.14 = 0.01 and 0.18− 0.17 = 0.01), which can be interpreted as
the reduction in prostate cancer mortality under DES compared with placebo that
is due to the DES effect on mortality from other causes. That is, the total effect of
DES on prostate cancer mortality is not simply a consequence of a harmful effect
on death from other causes.
The validity of our estimates relies on the assumption that L is sufficient to
adjust for the common causes of Yk and Dk. This assumption would be violated
if other factors, such as unmeasured comorbidities, exert effects on both Yk and
Dk. Also, our approach relies on the absence of time-varying common causes of the
event of interest and the competing event in many settings. In future work, we will
generalize our approach to allow for time-varying covariates.
7. Discussion
We have defined separable effects as new estimands to promote causal reasoning
in competing event settings. The separable effects are motivated by hypothetical
interventions, in which a time-fixed treatment is decomposed into distinct compo-
nents, and each component can be assigned different values.
Therefore, to define and interpret the separable effects, investigators must use
their subject-matter knowledge to explicitly articulate a hypothetical decomposi-
tion of the treatment. An explicit consideration of this decomposition helps assess
the plausibility of the assumptions and guides the design of future experiments to
empirically verify the effects.
Classical statistical estimands fail to provide the same information as the sep-
arable effects (see Young et al [1] for a detailed discussion of interpretation and
identification of counterfactual contrasts in classical estimands for competing event
settings). In particular, the cumulative incidence functions of the event of interest
and the competing event do not clarify the mechanism by which treatment exerts
effects on the event of interest, even if these outcomes are considered jointly in an
ideal randomized trial. Furthermore, estimands on the hazard scale, e.g. subdis-
tribution hazards and cause-specific hazards, do not have a straightforward causal
interpretation and thus cannot solve the problem [1, 4].
Identification of separable effects requires, even in a perfectly executed random-
ized trial, adjustment for pretreatment variables that are common causes of the
event of interest and the competing event. However, this strong condition is also
13
needed for the causal interpretation of analysis of trials targeting conventional esti-
mands such as controlled direct effects or counterfactual contrasts of hazard func-
tions [1].
Separable direct and indirect effects have conceptual similarities with pure (nat-
ural) effects in mediation analysis [9, 10]. In particular, the total effect can be
expressed as a sum of separable direct and indirect effects. However, unlike natu-
ral effects in mediation analysis, separable effects are single-world quantities whose
identification does not involve cross-world independencies. Therefore, separable
effects can, in principle, be empirically verified.
For simplicity, we have considered settings in which the treatment A is randomly
assigned. For example, we illustrated the application of standard time-to-event
methods to estimate the separable effects in a prostate cancer randomized trial.
However, our approach can be easily extended to analyses of observational studies
under the additional assumption of no unmeasured confounding for the effect of
treatment on both the competing event and the event of interest.
Finally, the idea of separable effects is not only relevant to settings in which the
outcome of interest is a time-to-event. Many practical settings involve intermedi-
ate outcomes that are ill-defined after the occurrence of a terminating event. For
example, we may be interested in treatment effects on outcomes such as quality of
life or cognitive function, and these outcomes are meaningless after death. We aim
to study separable effects in such settings in future research.
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A
AY
AD
Y1
D1
Figure 1. Directed acyclic graph for a trial with a randomized base-
line treatment A, such that AY and AD are deterministic functions
(bold arrows) of A, competing event D1 and event of interest Y1 at
time 1 of follow-up, with D1 measured just before Y1.
A
AY
AD
Y1
D1
Y2
D2
UY D
Figure 2. Extension of the causal directed acyclic graph in Figure
1 which includes an unmeasured common cause UY D which violates
conditions ∆1 and ∆2.
A
AY
AD
Y1
D1
Y2
D2
UY
UD
Figure 3. Extension of the directed acyclic graph in Figure 1 which
includes unmeasured common causes UY and UD, which are expected
to exist but do not violate conditions ∆1 and ∆2.
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A
AY
AD
Y1
D1
Y2
D2
L UY
Figure 4. Conditions ∆1 and ∆2 are valid if the common cause L
of Yk and Dk is measured.
A
AY | aY
AD | aD
Y1
aY ,aD
D1
aY ,aD
Y2
aY ,aD
D2
aY ,aD
L
Figure 5. Single world intervention template (SWIT) that describes
a scenario with interventions on AY and AD.The unmeasured common
causes UY and UD have been omitted to avoid clutter.
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A
AY
AD
Y1
D1
Y2
D2
L
C1 C2
Figure 6. Directed acyclic graph with loss to follow-up (Ck). To
avoid clutter, we have removed arrows from Ck into Yk and from Ck
into Dk for k ∈ {1, 2}.
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A
AY | aY
AD | aD
Y1
aY ,aD,c¯1
D1
aY ,aD,c¯1
Y2
aY ,aD,c¯2
D2
aY ,aD,c¯2
L
C1 | c1 C2 | c2
Figure 7. Single world intervention graph (SWIG) that describes a
scenario with interventions on AY , AD and C¯k. To avoid clutter, we
have removed from Ck into Yk and from Ck into Dk for k ∈ {1, 2}.
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Figure 8. Estimated cumulative incidence of (A) death from
prostate cancer and death from other causes using the Aalen-
Johansen estimator, and (B) death from prostate cancer under DES
(black), placebo (red) and the hypothetical treatment where the ef-
fect on death of other causes is removed (green) using the IP weighted
estimator νˆ1,aY ,aD,k.
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Appendix A. Some intuition about the magnitude of the separable
direct effects.
Consider the following scenarios:
• Scenario 1: If A has a null direct effect on the competing event (A9 Dk),
the separable direct effect is equal to the total effect.
• Scenario 2: If A has a null direct effect on the event of interest (A 9 Yk),
the indirect effect is equal to the total effect.
• Scenario 3: A has an average positive total effect on both Yk and Dk, and the
separable direct effect Pr(Y aY =1,aDk+1 = 1) vs. Pr(Y
aY =0,aD
k+1 = 1) is positive.
• Scenario 4: A has an average positive total effect on Yk and a negative total
effect onDk, and the separable direct effect Pr(Y
aY =1,aD
k+1 = 1) vs. Pr(Y
aY =0,aD
k+1 =
1) is negative.
To provide some intuition about the magnitude of the separable effects across
these scenarios, we conducted simulations under the following data generating pro-
cess:
(1) Draw L1 ∼ Bernoulli[p = 0.25].
(2) Draw AY ∼ Bernoulli[p = 0.5].
(3) Draw AD ∼ Bernoulli[p = 0.5].
(4) Define A = a if AY = a and AD = a.
(5) Set D0 = Y0 = 0.
(6) For each k ∈ {0, K},
• if Dk = Yk = 0,
draw Dk+1 ∼ Bernoulli[p = ηDψk(AY , AD, L1, L2)], where
ψk(AY , L1) = expit(ω0 + ω1,kk + ω2AY + ω3L1)
if Dk+1 = 0,
draw Yk+1 ∼ Bernoulli(p = ηY λk(AD, L1)), where
λk(AD, L1) = expit(ξ0 + ξ1,kk + ξ2AD + ξ3L1)
if Dk+1 = 1, set Yk+1 = 0.
• else, define Dk+1 = Dk,Yk+1 = Yk.
Scenario 1 is illustrated in Figure 9a, which was generated using the coefficients
from the first row of Table 2 with ξ2 = 0.
Scenario 2 illustrated in Figure 9b, which was generated using the coefficients
from the second row of Table 2.
Scenario 3 is illustrated in Figure 9c, which was generated using the coefficients
from the third row of Table 2.
Scenario 4 is illustrated in Figure 9d, where data were generated from the forth
row of Table 2.
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Figure 9. Counterfactual outcomes under the data generating
mechanisms from Table 2.
To provide additional intuition about the magnitude of the separable effects, it
may be helpful to consider two hypothetical sets of individuals (Table 3).
First, the hypothetical set Q includes individuals i ∈ Q who would experience
the competing event at time ti < k under full treatment (that is, AY = 1, AD = 1),
and would experience the event of interest at a time si, where ti < si < k, under the
hypothetical treatment with no separable indirect effect (that is, AY = 1, AD = 0),
see Table 3. Heuristically, this happens if the hypothetical treatment delays the
competing event such that the event of interest is allowed to occur. If Q comprises
a large fraction of the population, we would expect the total effect and the separable
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Scenario αY ω1 ω2 ω3 αD ξ1 ξ2 ξ3
1 0.01 0 10 5 0.03 0 0 5
2 0.01 0 0 5 0.03 0 5 5
3 0.01 0 10 5 0.03 0 5 5
4 0.01 0 10 5 0.03 0 -5 5
Table 2. Coefficients for the data generating mechanism of the ex-
amples in Appendix A.
direct effect to be different, because competing events would make it impossible for
the event of interest to occur under full treatment, but not under the hypothetical
treatment.
Second, consider a hypothetical set R such that all individuals j ∈ R would
experience the competing event at time tj < k under full treatment, but would
either experience the competing event at sj, where sj < k, or not experience any
event before k under the hypothetical treatment. That is, the subjects in R will
not experience the event of interest before k under the hypothetical treatment,
regardless of the time at which the competing event occurs. If R comprises a large
fraction of the population, the total effect and the separable direct effect on the
event of interest will be close.
Table 3. Outcomes at time k in subgroups Q and R.
Treatment Outcomes at k in Q Outcomes at k in R
AY = 1, AD = 1 (Yk = 0, Dk = 1) (Yk = 0, Dk = 1)
AY = 1, AD = 0 (Yk = 1, Dk = 0) (Yk = 0, Dk = 1) or (Yk = 0, Dk = 0)
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Appendix B. Conditional Independencies that imply the dismissible
component conditions.
We expressed the dismissible component conditions ∆1 and ∆2 in terms of equal-
ities of hazard functions. We now show that these equalities are implied by certain
counterfactual independencies that can be read directly off of successive single world
transformation of a causal DAG.
B.0.1. Hypothetical trial. Suppose that each component of A is randomly assigned
in a hypothetical 4-arm trial G. To indicate that the random variables are defined
with respect to G, let AY (G) and AD(G) be the value of AY and AD observed under
G, respectively. We assume that AY (G) and AD(G) are randomized independently
of each other to values in {0, 1}, that is AY (G) ⊥ AD(G). Assume no losses to
follow-up. Define the independencies
Yk+1(G) ⊥ AD(G) | AY (G), Yk(G) = 0, Dk+1(G) = 0, L(G),(12)
Dk+1(G) ⊥ AY (G) | AD(G), Dk(G) = 0, Yk(G) = 0, L(G).(13)
B.1. Conditions that ensure ∆1 and ∆2. Since AY (G) and AD(G) are ran-
domly assinged, conditional exchangeability is satisfied in the trial G, such that
Y¯ aY ,aDK+1 (G), D¯
aY ,aD
K+1 (G) ⊥ AY (G), AD(G) | L(G),
where aY , aD ∈ {0, 1}. In the special case where aY = aD, this conditional ex-
changeability condition is the same as the conditional exchangeability condition in
the main text.
Furthermore, we assume consistency in G, that is, if AY = aY and AD = aD then
Y aY ,aDk+1 (G) = Yk+1(G)
DaY ,aDk+1 (G) = Dk+1(G),
where aY , aD ∈ {0, 1}. This consistency condition is identical to the consistency
condition in the main text when aY = aD.
We assume positivity, that is
f(L(G) = l) > 0 =⇒
Pr(AY (G) = aY , AD(G) = aD | L(G) = l) > 0 w.p.1,(14)
which hold by design in G.
Let aY = 0, aD = 1 (an analogous argument holds when aY = 1, aD = 0). Using
exchangeability and consistency we find that
Pr(Yk+1(G) = 1 | Yk(G) = 0, Dk+1(G) = 0, AY (G) = 0, AD(G) = 1, L(G) = l)
= Pr(Y aY =0,aD=1k+1 (G) = 1 | Y aY =0,aD=1k (G) = 0, DaY =0,aD=1k+1 (G) = 0, AY (G) = 0, AD = 1, L(G) = l)
consistency, pos.
= Pr(Y aY =0,aD=1k+1 (G) = 1 | Y aY =0,aD=1k (G) = 0, DaY =0,aD=1k+1 (G) = 0, L(G) = l) exchangeability
(15)
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Figure 10. Directed acyclic graph describing a trial in which AY
and AD are randomized. Here, ∆1 and ∆2 hold.
Similarly, using (12), exchangeability and consistency we find
Pr(Yk+1(G) = 1 | Yk(G) = 0, Dk+1(G) = 0, AY (G) = 0, AD(G) = 1, L(G) = l)
= Pr(Yk+1(G) = 1 | Yk(G) = 0, Dk+1(G) = 0, AY (G) = 0, L(G) = l) due to (12)
= Pr(Yk+1(G) = 1 | Yk(G) = 0, Dk+1(G) = 0, AY (G) = 0, AD(G) = 0, L(G) = l) due to (12)
= Pr(Y aY =0,aD=0k+1 (G) = 1 | Y aY =0,aD=0k (G) = 0, DaY =0,aD=0k+1 (G) = 0, AY (G) = AD(G) = 0, L(G) = l)
consistency, pos.
= Pr(Y aY =0,aD=0k+1 (G) = 1 | Y aY =0,aD=0k (G) = 0, DaY =0,aD=0k+1 (G) = 0, L(G) = l) exchangeability
(16)
The derivations in (15) and (16) show that ∆1 is satisfied if condition (12) holds, as-
suming conditional exchangeability, positivity and consistency. We can use exactly
the same argument to show that condition ∆2 holds under conditional exchange-
ability, positivity, consistency and condition (13). Conditions (12) and (13) are
helpful in practice because these independences can be evaluated in causal graphs.
In particular, these conditions hold in Figure 10, where we have described a trial in
which AY and AD are randomly assigned independently of each other.
Appendix C. Proof of identifiability
We assume a Finest Fully Randomized Causally Interpretable Structured Tree
Graph (FFRCISTG) model [7]. The aim is to identify P
(
Y aY ,aD,c¯=0k = 1
)
as a
function of the factual data, in which A is randomized. To do this, we will initially
consider a scenario in which both AY and AD are randomized, that is, we consider
a 4 arm trial G, as described in Appendix B. Hereafter we omit the string ’(G)’
after the random variables, e.g. AY (G) = AY , to avoid clutter. We will provide a
proof for the scenario with a measured pretreatment covariate L and censoring Ck.
The results will immediately hold in simpler scenarios, e.g. by defining L or Ck to
be the empty set.
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C.1. Indentifiabilty conditions in the presence of censoring. First, we gen-
eralize the identifiability conditions to allow for censoring. Assume that subjects
may be lost to follow-up, and that the losses to follow-up can depend on AY , AD
and L, as suggested in Figure 6. Further, assume that the losses to follow-up are
independent of future counterfactual events (’independent censoring’). To be more
precise, we consider a setting in which we intervened such that no subject was lost to
follow-up. Let Ck ∈ {0, 1} be an indicator of loss to follow-up at k. Let DaY ,aD,c¯=0k
and Y aY ,aD,c¯=0k be the counterfactual values of Yk and Dk when AY is set to a
∗, AD
is set to a, and follow-up is ensured at all times.
In a continuous time setting, it is usually assumed that two events cannot occur
at the same point in time. In our discrete time setting with pretreatment covariates
L and censoring Ck, we define a temporal order
(L,AD, AY , C1, D1, Y1, C2, D2, Y2, ..., CK+1, DK+1, YK+1).
For all k ∈ {0, K} we consider the following conditions. First, we extend the
exchangeability conditions from Section 5.1,
E1 : Y¯ a,c¯=0K+1 , D¯
a,c¯=0
K+1 ⊥ A | L
E2 : Ya,c¯=0k+1 ,D
a,c¯=0
k+1 ⊥ Ck+1 | Yk = Dk = C¯k = 0, L, A.
Here, as in Section 5.1, E1 holds when A ≡ AY ≡ AD are randomized. E2 requires
that losses to follow-up are independent of future counterfactual events, given the
measured past. This condition is similar to the ’independent censoring’ condition
that is assumed to hold in classical randomized trials [1].
Furthermore, we require a consistency condition such that if AY = aY , AD = aD
and C¯k = 0, then Yk = Y
aY ,aD,c¯=0
k and Dk = D
aY ,aD,c¯=0
k , and still we only observe
scenarios where a∗ = a. The consistency condition ensures that if an individual
has a data history consistent with the intervention under a counterfactual scenario,
then the observed outcome is equal to the counterfactual outcome.
Similar to Section 5.1, the exchangeability and consistency conditions are conven-
tional in the causal inference literature. We also require an extra positivity condition
f(A = a, Yk = 0, Dk = 0, C¯k = 0, L = l) > 0 =⇒
Pr(Ck+1 = 0 | Yk = 0, Dk = 0, C¯k = 0, L = l, A = a) > 0 w.p.1,
for a = {0, 1} and l ∈ L, which ensures that for any possible history of treatment
assignments and covariates among those who are event-free and uncensored at k,
some subjects will remain uncensored at k + 1.
Finally, we rely on two dismissible component conditions which generalize the
conditions in Section 5, by allowing for a hypothetical intervention to eliminate
censoring at all times.
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Dismissible component conditions:
∆1c : Pr(Y
aY ,aD=1,c¯=0
k+1 = 1 | Y aY ,aD=1,c¯=0t = 0, DaY ,aD=1,c¯=0k+1 = 0, L = l)
= Pr(Y aY ,aD=0,c¯=0k+1 = 1 | Y aY ,aD=0,c=0t = 0, DaY ,aD=0,c=0k+1 = 0, L = l)
∆2c : Pr(D
aY =1,aD,c¯=0
k+1 = 1 | Y aY =1,aD,c¯=0k = 0, DaY =1,aD,c¯=0k = 0, L = l)
= Pr(DaY =0,aD,c¯=0k+1 = 1 | Y aY =0,aD,c=0k = 0, DaY =0,aD,c=0k = 0, L = l).
Under these conditions, Pr(Y aY ,aD,c¯=0K+1 = 1) is identified from (7).
C.2. Proof of identifiability. We consider the counterfactual outcomes in a set-
ting where aY = 0 and aD = 1 (analogous arguments holds for the setting where
aY = 1 and aD = 0), and we use laws of probability as well as ∆1c and ∆2c to
express
= Pr(Y aY =0,aD=1,c¯=0K+1 = 1)
=
∑
l
[
Pr(Y aY =0,aD=1,c¯=0K+1 = 1 | L = l)
]
Pr(L = l)
=
∑
l
[ K∑
s=0
Pr(Y aY =0,aD=1,c¯=0s+1 = 1 | DaY =0,aD=1,c¯=0s+1 = Y aY =0,aD=1,c¯=0s = 0, L = l)
s∏
j=0
[
Pr(DaY =0,aD=1,c¯=0j+1 = 0 | DaY =0,aD=1,c¯=0j = Y aY =0,aD=1,c¯=0j = 0, L = l)
× Pr(Y aY =0,aD=1,c¯=0j = 0 | DaY =0,aD=1,c¯=0j = Y aY =0,aD=1,c¯=0j−1 = 0, L = l)
]]
Pr(L = l)
=
∑
l
[ K∑
s=0
Pr(Y aY =0,aD=0,c¯=0s+1 = 1 | DaY =0,aD=0,c¯=0s+1 = Y aY =0,aD=0,c¯=0s = 0, L = l)
s∏
j=0
[
Pr(DaY =1,aD=1c¯=0j+1 = 0 | DaY =1,aD=1c¯=0j = Y aY =1,aD=1c¯=0j = 0, L = l)
× Pr(Y aY =0,aD=0,c¯=0j = 0 | DaY =0,aD=0,c¯=0j = Y aY =0,aD=0,c¯=0j−1 = 0, L = l)
]]
Pr(L = l),
=
∑
l
[ K∑
s=0
Pr(Y a=0,c¯=0s+1 = 1 | Da=0,c¯=0s+1 = Y a=0,c¯=0s = 0, L = l)
s∏
j=0
[
Pr(Da=1c¯=0j+1 = 0 | Da=1c¯=0j = Y a=1c¯=0j = 0, L = l)
× Pr(Y a=0,c¯=0j = 0 | Da=0,c¯=0j = Y a=0,c¯=0j−1 = 0, L = l)
]]
Pr(L = l),
(17)
where Y aY ,aD,c¯=0−1 and Y
aY ,c¯=0
−1 are empty sets.
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For s ≥ 0, let us consider the term
Pr(Y a,c¯=0s+1 = 1 | Da,c¯=0s+1 = Y a,c¯=0s = 0, L)
= Pr(Y a,c¯=0s+1 = 1 | Da,c¯=0s+1 = Y a,c¯=0s = Y0 = D0 = C¯0 = 0, L)
=
Pr(Y a,c¯=0s+1 = 1, D¯
a,c¯=0
s+1 = Y¯
a,c¯=0
s = 0 | Y0 = D0 = C¯0 = 0, A = a, L)
P (D¯a,c¯=0s+1 = Y¯
a,c¯=0
s = 0 | Y0 = D0 = C¯0 = 0, A = a, L)
,
where we use the fact that all subjects are event-free and uncensored at k = 0 in
the 2nd line, and laws of probability and E1 in the 3rd line. Then, we use positivity
and E2 to find
Pr(Y a,c¯=0s+1 = 1 | Da,c¯=0s+1 = Y a,c¯=0s = Y0 = D0 = C¯0 = 0, A = a, L)
=
Pr(Y a,c¯=0s+1 = 1, D¯
a,c¯=0
s+1 = Y¯
a,c¯=0
s = 0 | Y0 = D0 = C¯1 = 0, A = a, L)
P (D¯a,c¯=0s+1 = Y¯
a,c¯=0
s = 0 | Y0 = D0 = C¯1 = 0, A = a, L)
= Pr(Y a,c¯=0s+1 = 1 | Da,c¯=0s+1 = Y a,c¯=0s = Y0 = D0 = C¯1 = 0, A = a, L).
(18)
Similarly, if s = 1 we use consistency, a new step like (18), and consistency to find
that
Pr(Y a,c¯=02 = 1 | Da,c¯=02 = Y a,c¯=01 = Y0 = D0 = C¯1 = 0, A = a, L)
= Pr(Y a,c¯=02 = 1 | Da,c¯=02 = Y1 = D1 = C¯1 = 0, A = a, L)
= Pr(Y a,c¯=02 = 1 | Da,c¯=02 = Y1 = D1 = C¯2 = 0, A = a, L)
= Pr(Y2 = 1 | Y1 = D2 = C¯2 = 0, A = a, L).
If s > 1, we use consistency to find
Pr(Y a,c¯=0s+1 = 1 | Da,c¯=0s+1 = Y a,c¯=0s = Y0 = D0 = C¯1 = 0, A = a, L)
= Pr(Y a,c¯=0s+1 = 1 | Da,c¯=0s+1 = Y a,c¯=0s = Y1 = D1 = C¯1 = 0, A = a, L).
(19)
Then, we repeat the steps in (18) and (19) to find that for all s ∈ (1, 2, ..., K+1),
Pr(Y a,c¯=0s+1 = 1 | Dac¯=0s+1 = Y a,c¯=0s = Y0 = D0 = C¯0 = 0, A = a, L)
= Pr(Ys+1 = 1 | Ds+1 = Ys = C¯s+1 = 0, A = a, L).
(20)
Similarly, for Da,c¯=0s+1 we could follow the same steps as for Y
a,c¯=0
s+1 to express
Pr(Da,c¯=0s+1 = 1 | Da,c¯=0s = Y a,c¯=0s = Yk = Dk = C¯k = 0, A = a, L)
= Pr(Ds+1 = 1 | Ds = Ys = C¯s+1 = 0, A = a, L).
(21)
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Using the results in (17), (20) and (21), we find that
Pr(Y aY ,aD,c¯=0K+1 = 1)
=
∑
l
[ K∑
s=0
Pr(Ys+1 = 1 | Ds+1 = Ys = C¯s+1 = 0, A = aY , L = l)
s∏
j=0
[
Pr(Dj+1 = 0 | Dj = Yj = C¯j+1 = 0, A = aD, L = l)
× Pr(Yj = 0 | Dj = Yj−1 = C¯j = 0, A = aY , L = l)
]]
Pr(L = l).
In words, we have derived that Pr(Y aY ,aD,c¯=0K+1 = 1) is identified from a trial in
which only subjects with (AY = AD = A) are observed, i.e. in a trial in which A
is randomized. Hence, in practice we only need data from the treatment arms in
which A ≡ AY ≡ AD ∈ {0, 1}.
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Appendix D. Proof of weighted representations
For the ease of exposition, define
W ′C,k(aY ) =
1∏k
j=0 Pr(Cj+1 = 0 | C¯j = Dj = Yj = 0, L = l, A = aD)
.
Consider the expression
E[WC,k(aY )WD,k(aY , aD)Yk+1(1− Yk)(1−Dk+1) | A = aY ]
=E[W ′C,k(aY )WD,k(aY , aD)Yk+1(1− Yk)(1−Dk+1)(1− C¯k+1) | A = aY ]
=
∑
l
∑
y¯k+1
∑
d¯k+1
[f(y¯k+1, dk+1, ck+1, l | A = aY )W ′C,k(a)WD,k(aY , aD)
× yk+1(1− yk)(1− dk+1)(1− ck+1)]
=
∑
l
[f(Yk+1 = 1, Yk = Dk+1 = C¯k+1 = 0, l | A = aY )W ′C,k(aY )WD,k(aY , aD)]
=
∑
l
[Pr(Yk+1 = 1 | Yk = Dk+1 = C¯k+1 = 0, l, A = aY )
× Pr(Dk+1 = 0 | C¯k+1 = D¯k = Y¯k = 0, l, A = aY )
× Pr(Ck+1 = 0 | D¯k = Y¯k = C¯k = 0, l, A = aY )
× f(Y¯k = D¯k = C¯k = 0, L = l | aY )
×W ′C,k(aY )WD,k(aY , aD)]
where we use the definition of expected value, the fact that Yk and Dk are binary,
and laws of probability.
We use laws of probability to express f(Y¯k = D¯k = C¯k = 0, l | A = aY ) as
Pr(Yk = 0 | C¯k = Dk = Yk−1 = 0, l, A = aY )
× Pr(Dk = 0 | C¯k = Dk−1 = Yk−1 = 0, l, A = aY )
× Pr(Ck = 0 | Dk−1 = Yk−1 = C¯k−1 = 0, l, A = aY )
× f(Y¯k−1 = D¯k−1 = 0, C¯k−1 = 0, l | A = aY ),
where any variable indexed with a number m < 0 is defined to be the empty set.
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Arguing iteratively for k − 1, k − 2, ..., 0 we find that
E[W ′C,k(aY )WD,k(aY , aD)Yk+1(1− Yk)(1−Dk+1)(1− Ck+1) | A = aY ]
=
∑
l
[
Pr(Yk+1 = 1 | Yk = Dk+1 = C¯k+1 = 0, l, A = aY )
k∏
j=0
{
Pr(Dj+1 = 0 | C¯j+1 = Dj = Yj = 0, L = l, A = aY )
× Pr(Yj = 0 | C¯j = Dj = Yj−1 = 0, L = l, A = aY )
× Pr(Cj+1 = 0 | D¯j = Y¯j = C¯j = 0, L = l, aY )
}
×Pr(L = l)W ′C,k(aY )WD,k(aY , aD)
]
,
We plug in the expression for W ′C,k(aY ) to get
=
∑
l¯
[Pr(Yk+1 = 1 | Yk = Dk+1 = C¯k+1 = 0, L = l, A = aY )
×
k∏
j=0
{
Pr(Dj+1 = 0 | C¯j+1 = Dj = Yj = 0, L = l, A = aY )
× Pr(Yj = 0 | C¯j = Dj = Yj−1 = 0, L = l, A = aY )
}
× Pr(L = l)WD,k(aY , aD)],
We plug in the expression for the weights WD,k(aY , aD) to get
=
∑
l¯
[Pr(Yk+1 = 1 | Yk = Dk+1 = C¯k+1 = 0, L = l, A = aY )
×
k∏
j=0
{
Pr(Dj+1 = 0 | C¯j+1 = Dj = Yj = 0, L = l, A = aD)
× Pr(Yj = 0 | C¯j = Dj = Yj−1 = 0, L = l, A = aY )
}
,
×Pr(L = l)]
and the final expression is equal to (7).
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L UY
UD
Figure 11. Single world intervention template (SWIT) that de-
scribes a scenario with interventions on AY , AD and C¯k. Even if
UY and UD are unmeasured, ∆1 and ∆2 hold.
Appendix E. Exploring the dismissible component conditions
By considering causal graphs, we provide some insight into the interpretation of
assumptions ∆1 and ∆2.
E.1. Scenario in which the dismissible component conditions are satis-
fied. Consider the study from Appendix B in which AY and AD were random-
ized without loss to follow-up, which ensures positivity and exchangeability. Fur-
thermore, we assume that the usual assumptions about consistency is satisfied; if
AY = aY ,AD = aD, then Yk = Y
aY ,aD
k .
Assume that the causal structure in the single world intervention template (SWIT)
of Figure 5 holds. Here, AY is d-separated from both Y
aY ,aD
k and D
aY ,aD
k for k ∈ 1, 2.
Similarly AD is d-separated from both Y
aY ,aD
k and D
aY ,aD
k . Hence, under the as-
sumptions about positivity and consistency, we can identify the following joint law
from the g-formula,
Pr(Y aY ,aD2 = 1, Y
aY ,aD
1 = 0, D
aY ,aD
2 = 0, D
aY ,aD
1 = 0 | L)
= Pr(D1 = 0 | AY = aY , AD = aD, L) Pr(Y1 = 0 | D1 = 0, AY = aY , AD = aD, L)
×Pr(D2 = 0 | D1 = 0, Y1 = 0, AY = aY , AD = aD, L)
×Pr(Y2 = 1 | D2 = 0, D1 = 0, Y1 = 0, AY = aY , AD = aD, L)
= Pr(D1 = 0 | AD = a, L) Pr(Y1 = 0 | D1 = 0, AY = aY , L)
×Pr(D2 = 0 | D1 = 0, Y1 = 0, AD = aD, L) Pr(Y2 = 1 | D2 = 0, D1 = 0, Y1 = 0, AY = aY , L),
(22)
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where the last equality follows due to conditional independences that we read off
the causal graph. Similarly, we can identify
Pr(Y aY ,aD1 = 0, D
aY ,aD
2 = 0, D
aY ,aD
1 = 0 | L)
= Pr(D1 = 0 | AD = aD, L) Pr(Y1 = 0 | D1 = 0, AY = aY , L)
×Pr(D2 = 0 | D1 = 0, Y1 = 0, AD = aD, L).
(23)
Using laws of total probability,
Pr(Y aY ,aD2 = 1 | Y aY ,aD1 = 0, DaY ,aD2 = 0, DaY ,aD1 = 0, L)
=
Pr(Y aY ,aD2 = 1, Y
aY ,aD
1 = 0, D
aY ,aD
2 = 0, D
aY ,aD
1 = 0 | L)
Pr(Y aY ,aD1 = 0, D
aY ,aD
2 = 0, D
aY ,aD
1 = 0 | L)
= Pr(Y2 = 1 | D2 = 0, D1 = 0, Y1 = 0, AY = aY , L).
(24)
Hence,
= Pr(Y aY ,aD=12 = 1 | Y aY ,aD=11 = 0, DaY ,aD=12 = 0, DaY ,aD=11 = 0, L)
= Pr(Y aY ,aD=02 = 1 | Y aY ,aD=01 = 0, DaY ,aD=02 = 0, DaY ,aD=01 = 0, L),
that is ∆1 is satisfied at k = 2. Using the same argument, we can derive that
∆2 is satisfied for k = 2, and both ∆1 and ∆2 will be satisfied for k = 1. That
is, Figure 5 implies that ∆1 and ∆2 hold. Furthermore, we could use exactly the
same derivations to find that ∆1 and ∆2 hold in Figure 11, even if UY and UD are
unmeasured.
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Figure 12. Single world intervention template (SWIT) of a scenario
in which ∆1 and ∆2 are not implied by the graph.
E.2. Scenario in which the dismissible component conditions are not nec-
essarily satisfied. Consider the SWIT in Figure 12, which only differs from Figure
5 in the variable UY that is an unmeasured common cause of Y1 and D1. Here we
read off Figure 12 to find that
Pr(Y aY ,aD1 = 1 | DaY ,aD1 = 0, L)
= Pr(Y1 = 1 | D1 = 0, AY = aY , AD = aD, L),
(25)
However, we cannot conclude from the graph that
Pr(Y1 = 1 | D1 = 0, AY = aY , AD = 1, L)
= Pr(Y1 = 1 | D1 = 0, AY = aY , A = 0, L)
(26)
because there is an open collider path aD → D1 ← UY D → Y1. Hence, we cannot
conclude that the graph in Figure 12 implies ∆1, and our results do not allow us
to identify Pr(Y aY ,aD1 = 1) in this scenario. The unmeasured common cause UY D
of Yk and Dk′ for k, k
′ ∈ (0, 1, ..., K + 1) leads to violation of ∆1 and ∆2.
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Appendix F. Simulations
Here we present simulations from 5 scenarios to illustrate the finite sample perfor-
mance of the separable effects. We consider settings where the dismissible compo-
nent conditions are satisfied, but also settings where these conditions are violated.
Furthermore, we consider coverage under violation of the parametric model assump-
tions.
In each scenario, we simulated two randomized experiments in which 400 and
2000 subjects were randomly assigned to treatment A ∈ {0, 1}, respectively. To
assess finite sample behavior, we calculated confidence intervals for 3 time points
by simulating each experiment 500 times, and for each of these experiments we
created non-parametric percentile bootstrap confidence intervals from 500 bootstrap
samples.
The true cumulative incidences from the simulation scenarios are shown in Figure
13. Generally, our simulations confirm that the g-formula and IPW estimators
perform satisfactory when the identifiability conditions are satisfied.
F.1. Data generating mechanism. For each individual, the data were gener-
ated from the following algorithm, where we have omitted i subscripts to indicate
inidivuals:
(1) Draw L1 ∼ Bernoulli[p = 0.25].
(2) Draw L2 ∼ Bernoulli[p = 0.2L1 + 0.8(1− L1)].
(3) Draw A ∼ Bernoulli[p = 0.5], and define AY ≡ AD ≡ A.
(4) Set D0 = Y0 = 0.
(5) For each k ∈ {0, K},
• if Dk = Yk = 0,
draw Dk+1 ∼ Bernoulli[p = αDψk(AY , AD, L1, L2)], where
ψk(AY , AD, L1, L2) = expit(ω0 + ω1,kk + ω2AY + ω3AD + ω4L1 + ω5L2
+ ω6AYL1 + ω7ADL1)(27)
if Dk+1 = 0,
draw Yk+1 ∼ Bernoulli(p = αY λk(AY , AD, L1, L2)), where
λk(AY , AD, L1, L2) = expit(ξ0 + ξ1,kk + ξ2AY + ξ3AD + ξ4L1 + ξ5L2
+ ξ6AYL1 + ξ7ADL1).(28)
if Dk+1 = 1, set Yk+1 = 0.
• else, define Dk+1 = Dk,Yk+1 = Yk.
The coefficients in each of the scenarios are found in Table 4 and the true cumu-
lative incidence curves of Yk+1, k ∈ {0, 99} is found in Figure 13.
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Scenario αY ξ1 ξ2 ξ3 ξ4 ξ5 ξ6 ξ7 αD ω1 ω2 ω3 ω4 ω5 ω6 ω7
1 0.01 0 10 0 5 0 0 0 0.03 0 0 -2 5 0 0 0
2 0.01 0 10 0 -2 5 0 0 0.03 0 0 -2 5 -2 0 0
3 0.01 0 10 0 5 -10 5 0 0.03 0 0 -2 5 -10 0 0
4 0.01 0 10 5 5 0 0 0 0.03 0 0 -2 5 0 0 0
5 0.01 0 10 0 -10 0 0 0 0.03 0 0 -2 0 0 0 0
Table 4. Data generating mechanism for the 7 simulation scenarios.
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F.2. Scenario 1: Dismissible component conditions hold and no model
mis-specification. Data were generated from the simple setting described by the
first row in Table 4; that is, there is a causal effect of (i) AY on Yk, (ii) AD on Dk,
and (iii) L1 on both Yk and Dk. Here, both the dismissible component conditions
hold conditional on L1.
To estimate the separable effects, we fitted the following models
logit[P̂r(Yk = 1 | Dk = Yk−1 = 0, A, L1, L2)] = θ0,k + θ1A+ θ2L1 + θ3L2(29)
logit[P̂r(Dk = 1 | Dk−1 = Yk−1 = 0, A, L1, L2)] = β0,k + β1A+ β2L1,(30)
which are correctly specified, even if model (29) includes a term θ3 that is redun-
dant. Thus, we would expect all our estimators to have nominal coverage, and this
is confirmed in Table 5; here, coverage is derived from estimated 95% confidence
intervals based on the parametric g-formula estimator (g-formula) and the weighted
estimators (νˆ1,aY ,aD,k and νˆ2,aY ,aD,k) for the trial with n = 400 subjects.
n = 400
Parameter Estimator k = 100 k = 75 k = 25
Pr(Y aY =1,aD=1k = 1) g-formula 0.95 0.94 0.93
non-parametric 0.95 0.94 0.95
Pr(Y aY =0,aD=0k = 1) g-formula 0.94 0.93 0.92
non-parametric 0.94 0.95 0.95
Pr(Y aY =1,aD=0k = 1) g-formula 0.95 0.96 0.94
νˆ1,aY ,aD,k 0.94 0.95 0.95
νˆ2,aY ,aD,k 0.96 0.95 0.95
Pr(Y aY =0,aD=1k = 1) g-formula 0.93 0.93 0.94
νˆ1,aY ,aD,k 0.92 0.90 0.95
νˆ2,aY ,aD,k 0.94 0.94 0.92
Table 5. Scenario 1.
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Scenario 2: Dismissible component conditions hold and minor model
mis-specification. In this scenario, there are causal effects of both L1 and L2 on
Yk and Dk (second row in Table 4). Both the dismissible component conditions
hold conditional on L1 and L2. We used regression models (29) and (30) for model
fitting.
Note that in this setting (29) is correctly specified, but (30) is mis-specified
because it does not include a term for L2. Thus, we would expect that the IPW
estimator that uses the correctly specified regression model ( νˆ2,aY ,aD,k) is unbiased,
but the parametric g-formula estimator and the other IPW estimator ( νˆ1,aY ,aD,k)
are biased because (30) is mis-specified. The results in Table 6, however, suggest
that all estimators have close to nominal coverage. This may be explained by the
fact that the model mis-specification is minor, and the magnitude of the separable
effects is small (see Figure 13).
n = 400
Parameter Estimator k = 100 k = 75 k = 25
Pr(Y aY =1,aD=1k = 1) g-formula 0.91 0.92 0.91
non-parametric 0.95 0.96 0.93
Pr(Y aY =0,aD=0k = 1) g-formula 0.94 0.94 0.93
non-parametric 0.93 0.93 0.93
Pr(Y aY =1,aD=0k = 1) g-formula 0.96 0.94 0.91
νˆ1,aY ,aD,k 0.93 0.95 0.93
νˆ2,aY ,aD,k 0.91 0.92 0.88
Pr(Y aY =0,aD=1k = 1) g-formula 0.94 0.93 0.93
νˆ1,aY ,aD,k 0.90 0.91 0.93
νˆ2,aY ,aD,k 0.93 0.94 0.94
Table 6. Scenario 2.
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Scenario 3: Dismissible component conditions hold and model mis-specification.
In this scenario, both the dismissible component conditions hold conditional on L1
and L2. Unlike Scenarios 1 and 2, we fitted the following regression models to the
simulated data,
logit[P̂r(Yk = 1 | Dk = Yk−1 = 0, A, L1, L2)] = θ0,k + θ1A+ θ2L1(31)
logit[P̂r(Dk = 1 | Dk−1 = Yk−1 = 0, A, L1, L2)] = β0,k + β1A+ β2L1 + β3L2.(32)
Here, (31) is mis-specified because it does not include a term for L2, but (32)
is correctly specified; thus the correctness of the model specifications are opposite
from Scenario 2. Also, L2 exerts larger effects on Yk and Dk in this setting compared
to Scenario 2.
The results in Table 7 illustrate that the IPW estimator νˆ1,aY ,aD,k is unbiased
because it relies on a correctly specified model, but the parametric g-formula esti-
mator and the other IPW estimator (νˆ2,aY ,aD,k) are biased – in particular, for shorter
follow-up times – because they rely on mis-specified regression models.
n = 400
Parameter Estimator k = 100 k = 75 k = 25
Pr(Y aY =1,aD=1k = 1) g-formula 0.93 0.95 0.91
non-parametric 0.93 0.93 0.94
Pr(Y aY =0,aD=0k = 1) g-formula 0.93 0.86 0.48
non-parametric 0.94 0.93 0.94
Pr(Y aY =1,aD=0k = 1) g-formula 0.93 0.94 0.93
νˆ1,aY ,aD,k 0.94 0.94 0.93
νˆ2,aY ,aD,k 0.91 0.72 0.56
Pr(Y aY =0,aD=1k = 1) g-formula 0.82 0.74 0.45
νˆ1,aY ,aD,k 0.95 0.95 0.94
νˆ2,aY ,aD,k 0.84 0.72 0.33
Table 7. Scenario 3.
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Scenario 4: Dismissible component conditions fail and model misspecifi-
cation. The dismissible component condition ∆2 fails in this scenario due to the
non-zero coefficient ω3 = 5; there is a direct effect AY → Dk for k ∈ {0, 100}. Yet
we fitted regression models (29) and (30) to the simulated data.
The simulations suggest that none of the estimators has nominal coverage for
Pr(Y aY =0,aD=1k+1 = 1). However, since dismissible component condition ∆1 holds
we can identify Pr(Y aY =1,aD=0k+1 = 1), as suggested by the nominal coverage for
this quantity in Table 8. Yet we cannot interpret a contrast Pr(Y aY =0,aD=1k+1 =
1) vs Pr(Y aY =1,aD=1k+1 = 1) as the separable direct effect of A, due to the violation of
the dismissible component condition.
n = 400
Parameter Estimator k = 100 k = 75 k = 25
Pr(Y aY =1,aD=1k = 1) g-formula 0.96 0.94 0.93
non-parametric 0.95 0.94 0.94
Pr(Y aY =0,aD=0k = 1) g-formula 0.93 0.93 0.92
non-parametric 0.93 0.93 0.95
Pr(Y aY =1,aD=0k = 1) g-formula 0.96 0.97 0.94
νˆ1,aY ,aD,k 0.94 0.96 0.94
νˆ2,aY ,aD,k 0.97 0.96 0.96
Pr(Y aY =0,aD=1k = 1) g-formula 0.05 0.05 0.07
νˆ1,aY ,aD,k 0.31 0.26 0.34
νˆ2,aY ,aD,k 0.05 0.04 0.12
Table 8. Scenario 4.
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Scenario 5: Dismissible component conditions hold and no model mis-
specification. In this scenario, L1 exerts (strong) causal effects on Yk but not on
Dk. Thus, all the dismissible component conditions hold marginally. To illustrate
that we obtain unbiased estimates even if L1 is not included in any of the regression
models, we fitted the parsimonious models,
logit[P̂r(Yk = 1 | Dk = Yk−1 = 0, A)] = θ0,k + θ1A.(33)
logit[P̂r(Dk = 1 | Dk−1 = Yk−1 = 0, A)] = β0,k + β1A,(34)
and the results in Table 9 show that all estimators have nominal coverage, even if
L1 is not included in the models.
n = 400
Parameter Estimator k = 100 k = 75 k = 25
Pr(Y aY =1,aD=1k = 1) g-formula 0.95 0.94 0.94
non-parametric 0.95 0.95 0.95
Pr(Y aY =0,aD=0k = 1) g-formula 0.94 0.94 0.93
non-parametric 0.95 0.94 0.94
Pr(Y aY =1,aD=0k = 1) g-formula 0.96 0.95 0.94
νˆ1,aY ,aD,k 0.97 0.96 0.95
νˆ2,aY ,aD,k 0.95 0.95 0.94
Pr(Y aY =0,aD=1k = 1) g-formula 0.93 0.94 0.94
νˆ1,aY ,aD,k 0.94 0.93 0.94
νˆ2,aY ,aD,k 0.94 0.94 0.94
Table 9. Scenario 5.
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Figure 13. True cumulative incidence curves for scenarios 1-5.
